Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET

Company Participants

Todd Tushla – Vice President of Investor Relations
Kyle Gano – Chief Executive Officer
Matt Abernethy – Chief Financial Officer
Eric Benevich – Chief Commercial Officer
Eiry Roberts – Chief Medical Officer

Conference Call Participants

Phil Nadeau – TD Cowen
Paul Matteis – Stifel
Tazeen Ahmad – Bank of America
Akash Tewari – Jefferies
Cory Kasimov – Evercore
David Amsellem – Piper Sandler
Malcolm Kuno – JPMorgan
Chris Shibutani – Goldman Sachs
Marc Goodman – Leerink Partners
Jeffrey Hung – Morgan Stanley
Charlie Moore – Baird
Mohit Bansal – Wells Fargo
Ash Verma – UBS
Sumant Kulkarni – Canaccord
Myles Minter – William Blair
Laura Chico – Wedbush Securities
Ami Fadia – Needham
Uy Ear – Mizuho
Malcolm Hoffman – BMO Capital Markets

Operator

Good day, everyone, and welcome to today’s Neurocrine Biosciences Reports Q4 and Fiscal Year 2024 Earnings Call. [Operator Instructions] Please note today’s call will be recorded, and I will be standing by should you need any assistance.

It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla.

Todd Tushla

Thank you, and a good Thursday afternoon to everyone. Welcome to Neurocrine Biosciences fourth quarter and full year 2024 earnings call.

Joining me today are Kyle Gano, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; and Eiry Roberts, Chief Medical Officer.

During our call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. We’ll go to Q&A after prepared remarks and as is our custom and with your help, we will try to get everyone’s questions.